

William J Calhoun

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/993386/publications.pdf>

Version: 2024-02-01

122
papers

11,400
citations

50566

48
h-index

32181

105
g-index

123
all docs

123
docs citations

123
times ranked

11145
citing authors

#	ARTICLE	IF	CITATIONS
1	Optical biosensing of markers of mucosal inflammation. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2022, 40, 102476.	1.7	7
2	The new era of add-on asthma treatments: where do we stand?. <i>Allergy, Asthma and Clinical Immunology</i> , 2022, 18, .	0.9	12
3	A Comprehensive Analysis of the Stability of Blood Eosinophil Levels. <i>Annals of the American Thoracic Society</i> , 2021, 18, 1978-1987.	1.5	19
4	Response to Parenteral Triamcinolone in Severe Asthma: A Useful Induced Phenotype for Clinicians?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 790-791.	2.5	2
5	<i>HSD3B1</i> genotype identifies glucocorticoid responsiveness in severe asthma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 2187-2193.	3.3	27
6	Outpatient Management of Chronic Asthma in 2020. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 561.	3.8	12
7	Management of Acute Asthma in Adults in 2020. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 563.	3.8	11
8	Why do asthma patients cough? New insights into cough in allergic asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 656-657.	1.5	3
9	Ethanol Exposure Impairs AMPK Signaling and Phagocytosis in Human Alveolar Macrophages: Role of Ethanol Metabolism. <i>Alcoholism: Clinical and Experimental Research</i> , 2019, 43, 1682-1694.	1.4	12
10	Pharmacoproteomics reveal novel protective activity of bromodomain containing 4 inhibitors on vascular homeostasis in TLR3-mediated airway remodeling. <i>Journal of Proteomics</i> , 2019, 205, 103415.	1.2	24
11	Forced Oscillometry: A New Tool for Assessing Airway Function—Is It Ready for Prime Time?. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 2861-2862.	2.0	7
12	Mucosal bromodomain-containing protein 4 mediates aeroallergen-induced inflammation and remodeling. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 1380-1394.e9.	1.5	49
13	National estimates of 30-day readmissions among children hospitalized for asthma in the United States. <i>Journal of Asthma</i> , 2018, 55, 695-704.	0.9	15
14	Race is associated with differences in airway inflammation in patients with asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 257-265.e11.	1.5	39
15	Biologic Therapy in Chronic Obstructive Pulmonary Disease. <i>Immunology and Allergy Clinics of North America</i> , 2017, 37, 345-355.	0.7	5
16	Diagnosis and Management of Asthma in Adults. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 279.	3.8	158
17	Activation of Human Peripheral Blood Eosinophils by Cytokines in a Comparative Time-Course Proteomic/Phosphoproteomic Study. <i>Journal of Proteome Research</i> , 2017, 16, 2663-2679.	1.8	15
18	Post-transplant native pneumonectomy for interstitial fibrosis and small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2017, 9, E1096-E1099.	0.6	2

#	ARTICLE	IF	CITATIONS
19	30-Day Readmissions in Hospitalized Adults With Asthma Exacerbations. <i>Chest</i> , 2016, 150, 1162-1165.	0.4	7
20	Cytokine-Induced Glucocorticoid Resistance from Eosinophil Activation: Protein Phosphatase 5 Modulation of Glucocorticoid Receptor Phosphorylation and Signaling. <i>Journal of Immunology</i> , 2016, 197, 3782-3791.	0.4	31
21	Biologic therapy in the management of asthma. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2016, 16, 375-382.	1.1	61
22	Effects of acute ethanol exposure on cytokine production by primary airway smooth muscle cells. <i>Toxicology and Applied Pharmacology</i> , 2016, 292, 85-93.	1.3	11
23	Impact of Age and Sex on Outcomes and Hospital Cost of Acute Asthma in the United States, 2011-2012. <i>PLoS ONE</i> , 2016, 11, e0157301.	1.1	57
24	Evolution of Multidisciplinary Translational Teams (MTTs): Insights for Accelerating Translational Innovations. <i>Clinical and Translational Science</i> , 2015, 8, 542-552.	1.5	35
25	Sex differences in hospital length of stay in children and adults hospitalized for asthma exacerbation. <i>Annals of Allergy, Asthma and Immunology</i> , 2015, 115, 533-535.e1.	0.5	5
26	Therapeutic potential of anti-IL-6 therapies for granulocytic airway inflammation in asthma. <i>Allergy, Asthma and Clinical Immunology</i> , 2015, 11, 14.	0.9	68
27	Asthma exacerbations and lung function in patients with severe or difficult-to-treat asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 1125-1127.e4.	1.5	50
28	The Role of Computed Tomography in Chronic Obstructive Pulmonary Diseases. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2015, 3, 594-596.	2.0	1
29	Asthma Is More Severe in Older Adults. <i>PLoS ONE</i> , 2015, 10, e0133490.	1.1	80
30	Clinical Implications of Having Reduced Mid Forced Expiratory Flow Rates (FEF25-75), Independently of FEV1, in Adult Patients with Asthma. <i>PLoS ONE</i> , 2015, 10, e0145476.	1.1	49
31	Assessing and Evaluating Multidisciplinary Translational Teams. <i>Evaluation and the Health Professions</i> , 2014, 37, 33-49.	0.9	34
32	Introduction to Asthma and Phenotyping. <i>Advances in Experimental Medicine and Biology</i> , 2014, 795, 5-15.	0.8	10
33	Ethanol metabolism, oxidative stress, and endoplasmic reticulum stress responses in the lungs of hepatic alcohol dehydrogenase deficient deer mice after chronic ethanol feeding. <i>Toxicology and Applied Pharmacology</i> , 2014, 277, 109-117.	1.3	24
34	Clinical Burden and Predictors of Asthma Exacerbations in Patients on Guideline-based Steps 4-6 Asthma Therapy in the TENOR Cohort. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2014, 2, 193-200.e3.	2.0	40
35	Unsupervised phenotyping of Severe Asthma Research Program participants using expanded lung data. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 1280-1288.	1.5	247
36	Conclusions and Future Directions. <i>Advances in Experimental Medicine and Biology</i> , 2014, 795, 335-343.	0.8	1

#	ARTICLE	IF	CITATIONS
37	Heterogeneity of Asthma in Society. <i>Advances in Experimental Medicine and Biology</i> , 2014, 795, 31-41.	0.8	4
38	Heterogeneity of Response to Therapy. <i>Advances in Experimental Medicine and Biology</i> , 2014, 795, 117-122.	0.8	0
39	Symptom-Based Controller Therapy: A New Paradigm for Asthma Management. <i>Current Allergy and Asthma Reports</i> , 2013, 13, 427-433.	2.4	1
40	P2X ₇ -Regulated Protection from Exacerbations and Loss of Control Is Independent of Asthma Maintenance Therapy. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 187, 28-33.	2.5	16
41	Predictors of response to tiotropium versus salmeterol in asthmatic adults. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 132, 1068-1074.e1.	1.5	100
42	Genome-wide association study identifies TH1 pathway genes associated with lung function in asthmatic patients. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 132, 313-320.e15.	1.5	98
43	Alcoholic lung injury: Metabolic, biochemical and immunological aspects. <i>Toxicology Letters</i> , 2013, 222, 171-179.	0.4	85
44	The CTSA as an Exemplar Framework for Developing Multidisciplinary Translational Teams. <i>Clinical and Translational Science</i> , 2013, 6, 60-71.	1.5	41
45	An Association between Arginine/Asymmetric Dimethyl Arginine Balance, Obesity, and the Age of Asthma Onset Phenotype. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 187, 153-159.	2.5	141
46	Strategies for Tailoring Asthma Treatment in Adults—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 136.	3.8	0
47	Aldose Reductase Inhibition Prevents Allergic Airway Remodeling through PI3K/AKT/GSK3 β Pathway in Mice. <i>PLoS ONE</i> , 2013, 8, e57442.	1.1	33
48	Severe Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 185, 356-362.	2.5	242
49	Comparison of Physician-, Biomarker-, and Symptom-Based Strategies for Adjustment of Inhaled Corticosteroid Therapy in Adults With Asthma. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 987.	3.8	166
50	Benralizumab—a humanized mAb to IL-5R α with enhanced antibody-dependent cell-mediated cytotoxicity—a novel approach for the treatment of asthma. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 113-118.	1.4	161
51	Strategies for Molecular Classification of Asthma Using Bipartite Network Analysis of Cytokine Expression. <i>Current Allergy and Asthma Reports</i> , 2012, 12, 388-395.	2.4	17
52	Airway microbiota and bronchial hyperresponsiveness in patients with suboptimally controlled asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 127, 372-381.e3.	1.5	598
53	Importance of hedgehog interacting protein and other lung function genes in asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 127, 1457-1465.	1.5	115
54	Safety of investigative bronchoscopy in the Severe Asthma Research Program. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 128, 328-336.e3.	1.5	65

#	ARTICLE	IF	CITATIONS
55	Obesity and asthma: An association modified by age of asthma onset. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 127, 1486-1493.e2.	1.5	330
56	Meta-analysis of genome-wide association studies of asthma in ethnically diverse North American populations. <i>Nature Genetics</i> , 2011, 43, 887-892.	9.4	736
57	Determinants of Exhaled Breath Condensate pH in a Large Population With Asthma. <i>Chest</i> , 2011, 139, 328-336.	0.4	61
58	How cytokines co-occur across asthma patients: From bipartite network analysis to a molecular-based classification. <i>Journal of Biomedical Informatics</i> , 2011, 44, S24-S30.	2.5	35
59	Omalizumab in Asthma. <i>Chest</i> , 2011, 139, 8-10.	0.4	4
60	Symptom-adjusted therapy in asthma: it is time to listen to our patients. <i>Expert Review of Clinical Immunology</i> , 2011, 7, 259-261.	1.3	1
61	Detrimental Effects of Environmental Tobacco Smoke in Relation to Asthma Severity. <i>PLoS ONE</i> , 2011, 6, e18574.	1.1	96
62	Proteomic Insights into Inflammatory Airway Diseases. <i>Current Proteomics</i> , 2011, 8, 84-96.	0.1	3
63	Bronchoprovocation testing in asthma: effect on exhaled monoxides. <i>Journal of Breath Research</i> , 2010, 4, 047104.	1.5	7
64	Phenotypic characterization of severe asthma. <i>Current Opinion in Pulmonary Medicine</i> , 2010, 16, 48-54.	1.2	15
65	Section 2. Exercise-Induced Bronchospasm: Albuterol versus Montelukast. <i>World Allergy Organization Journal</i> , 2010, 3, 23-30.	1.6	2
66	Predicting Intermediate Phenotypes in Asthma Using Bronchoalveolar Lavage-Derived Cytokines. <i>Clinical and Translational Science</i> , 2010, 3, 147-157.	1.5	62
67	Use of Exhaled Nitric Oxide Measurement to Identify a Reactive, at-Risk Phenotype among Patients with Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 181, 1033-1041.	2.5	252
68	Identification of Asthma Phenotypes Using Cluster Analysis in the Severe Asthma Research Program. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 181, 315-323.	2.5	1,820
69	Tiotropium Bromide Step-Up Therapy for Adults with Uncontrolled Asthma. <i>New England Journal of Medicine</i> , 2010, 363, 1715-1726.	13.9	467
70	A trial of clarithromycin for the treatment of suboptimally controlled asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 126, 747-753.	1.5	128
71	Levalbuterol versus albuterol. <i>Current Allergy and Asthma Reports</i> , 2009, 9, 401-409.	2.4	11
72	Effect of β_2 -adrenergic receptor polymorphism on response to longacting β_2 agonist in asthma (LARGE) Tj ETQq0 0 0 rgBT /Overlock 1 1754-1764.	6.3	213

#	ARTICLE	IF	CITATIONS
73	Biomarkers in asthma. <i>Current Opinion in Pulmonary Medicine</i> , 2009, 15, 12-18.	1.2	36
74	Non-invasive measurements of exhaled NO and CO associated with methacholine responses in mice. <i>Respiratory Research</i> , 2008, 9, 45.	1.4	18
75	Molecular phenotyping of severe asthma using pattern recognition of bronchoalveolar lavage-derived cytokines. <i>Journal of Allergy and Clinical Immunology</i> , 2008, 121, 30-37.e6.	1.5	114
76	Effect of Nebulized Arformoterol on Airway Function in COPD: Results from Two Randomized Trials. COPD: <i>Journal of Chronic Obstructive Pulmonary Disease</i> , 2008, 5, 25-34.	0.7	36
77	Alterations of the Arginine Metabolome in Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 178, 673-681.	2.5	116
78	Future directions in asthma management. <i>Expert Review of Clinical Immunology</i> , 2008, 4, 647-648.	1.3	0
79	Airway Lipoxin A ₄ Generation and Lipoxin A ₄ Receptor Expression Are Decreased in Severe Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 178, 574-582.	2.5	215
80	Lung function in adults with stable but severe asthma: air trapping and incomplete reversal of obstruction with bronchodilation. <i>Journal of Applied Physiology</i> , 2008, 104, 394-403.	1.2	270
81	Differential regulation of the transcriptional activity of the glucocorticoid receptor through site-specific phosphorylation. <i>Biologics: Targets and Therapy</i> , 2008, 2, 845.	3.0	28
82	Invasive Tests: Bronchoalveolar Lavage and Biopsy: The Scope of the Scope. , 2008, , 107-116.		1
83	IL4R α Mutations Are Associated with Asthma Exacerbations and Mast Cell/IgE Expression. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007, 175, 570-576.	2.5	133
84	Racemic = R Enantiomer: A Dual Citation. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007, 175, 628a-629.	2.5	0
85	Nebulized arformoterol in patients with COPD: A 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial. <i>Clinical Therapeutics</i> , 2007, 29, 261-278.	1.1	60
86	The Relationship Between Sleep and Asthma. <i>Sleep Medicine Clinics</i> , 2007, 2, 9-18.	1.2	9
87	Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. <i>Journal of Allergy and Clinical Immunology</i> , 2007, 119, 405-413.	1.5	838
88	The role of leukotrienes in airway inflammation. <i>Journal of Allergy and Clinical Immunology</i> , 2006, 118, 789-798.	1.5	107
89	Rebuttal by Drs. Ameredes and Calhoun. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 174, 972-974.	2.5	10
90	In vitro cytotoxicity of Manville Code 100 glass fibers: effect of fiber length on human alveolar macrophages. <i>Particle and Fibre Toxicology</i> , 2006, 3, 5.	2.8	28

#	ARTICLE	IF	CITATIONS
91	(R)-Albuterol for Asthma: Pro [a.k.a. (S)-Albuterol for Asthma: Con]. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 965-969.	2.5	36
92	Inhibition of phosphodiesterase 4 amplifies cytokine-dependent induction of arginase in macrophages. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2006, 290, L534-L539.	1.3	42
93	Enhanced nitric oxide production associated with airway hyporesponsiveness in the absence of IL-10. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2005, 288, L868-L873.	1.3	10
94	Alterations in Nitric Oxide and Cytokine Production with Airway Inflammation in the Absence of IL-10. Journal of Immunology, 2005, 175, 1206-1213.	0.4	15
95	Studies of the Biogenic Amine Transporters. XI. Identification of a 1-[2-[Bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine (GBR12909) Analog That Allosterically Modulates the Serotonin Transporter. Journal of Pharmacology and Experimental Therapeutics, 2005, 314, 906-915.	1.3	17
96	Superoxide Dismutase Inactivation in Pathophysiology of Asthmatic Airway Remodeling and Reactivity. American Journal of Pathology, 2005, 166, 663-674.	1.9	170
97	Regarding "Differential control of TH1 versus TH2 cell responses by the combination of low-dose steroids with β_2 -adrenergic agonists". Journal of Allergy and Clinical Immunology, 2005, 115, 424.	1.5	2
98	Modulation of GM-CSF release by enantiomers of β_2 -agonists in human airway smooth muscle. Journal of Allergy and Clinical Immunology, 2005, 116, 65-72.	1.5	31
99	Asthma variability in patients previously treated with β_2 -agonists alone. Journal of Allergy and Clinical Immunology, 2003, 112, 1088-1094.	1.5	74
100	Nocturnal Asthma. Chest, 2003, 123, 399S-405S.	0.4	55
101	Regulation of IL-1 β -induced GM-CSF production in human airway smooth muscle cells by carbon monoxide. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2003, 284, L50-L56.	1.3	38
102	Low-dose carbon monoxide reduces airway hyperresponsiveness in mice. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2003, 285, L1270-L1276.	1.3	57
103	MORE INFLAMMATION THAN LUNG IN EMPHYSEMA. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 730-731.	2.5	1
104	Anti-leukotrienes for asthma. Current Opinion in Pharmacology, 2001, 1, 230-234.	1.7	11
105	Current Outpatient Management of Asthma Shows Poor Compliance With International Consensus Guidelines. Chest, 1999, 116, 1638-1645.	0.4	84
106	Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction. Journal of Allergy and Clinical Immunology, 1998, 102, 935-942.	1.5	84
107	Effect of nedocromil sodium pretreatment on the immediate and late responses of the airway to segmental antigen challenge. Journal of Allergy and Clinical Immunology, 1996, 98, S46-S50.	1.5	13
108	Eosinophils and basophils in allergic airway inflammation. Journal of Allergy and Clinical Immunology, 1994, 94, 1250-1254.	1.5	22

#	ARTICLE	IF	CITATIONS
109	Increased Airway Inflammation with Segmental versus Aerosol Antigen Challenge. <i>The American Review of Respiratory Disease</i> , 1993, 147, 1465-1471.	2.9	95
110	Characteristics of Peripheral Blood Eosinophils in Patients with Nocturnal Asthma. <i>The American Review of Respiratory Disease</i> , 1992, 145, 577-581.	2.9	41
111	Enhanced Production of Oxygen Radicals in Nocturnal Asthma. <i>The American Review of Respiratory Disease</i> , 1992, 146, 905-911.	2.9	105
112	Enhanced Superoxide Production by Alveolar Macrophages and Air-Space Cells, Airway Inflammation, and Alveolar Macrophage Density Changes after Segmental Antigen Bronchoprovocation in Allergic Subjects. <i>The American Review of Respiratory Disease</i> , 1992, 145, 317-325.	2.9	206
113	Effect of an Experimental Rhinovirus 16 Infection on Airway Mediator Response to Antigen. <i>International Archives of Allergy and Immunology</i> , 1992, 99, 422-424.	0.9	6
114	The Role of Eosinophils in the Pathophysiology of Asthma. <i>Annals of the New York Academy of Sciences</i> , 1991, 629, 62-72.	1.8	46
115	Experimental Rhinovirus 16 Infection Potentiates Histamine Release after Antigen Bronchoprovocation in Allergic Subjects. <i>The American Review of Respiratory Disease</i> , 1991, 144, 1267-1273.	2.9	129
116	Human Neutrophil Elastase and Elastase/Alpha1-Antiprotease Complex in Cystic Fibrosis: Comparison with Interstitial Lung Disease and Evaluation of the Effect of Intravenously Administered Antibiotic Therapy. <i>The American Review of Respiratory Disease</i> , 1991, 144, 580-585.	2.9	122
117	Elevated Bronchoalveolar Lavage Fluid Histamine Levels in Allergic Asthmatics Are Associated with Increased Airway Obstruction. <i>The American Review of Respiratory Disease</i> , 1991, 144, 83-87.	2.9	148
118	Immediate and Late Airway Response of Allergic Rhinitis Patients to Segmental Antigen Challenge: Characterization of Eosinophil and Mast Cell Mediators. <i>The American Review of Respiratory Disease</i> , 1991, 144, 1274-1281.	2.9	291
119	Bronchoalveolar Lavage in Stable Asthmatics Does Not Cause Pulmonary Inflammation. <i>The American Review of Respiratory Disease</i> , 1990, 142, 100-103.	2.9	28
120	Studies of Bronchoalveolar Lavage Cells and Fluids in Pulmonary Sarcoidosis: I. Enhanced Capacity of Bronchoalveolar Lavage Cells from Patients with Pulmonary Sarcoidosis to Induce Angiogenesis In Vivo. <i>The American Review of Respiratory Disease</i> , 1989, 140, 1446-1449.	2.9	37
121	Studies of Bronchoalveolar Lavage Cells and Fluids in Pulmonary Sarcoidosis: II. Enhanced Capacity of Bronchoalveolar Lavage Fluids from Patients with Pulmonary Sarcoidosis to Induce Cell Movement In Vitro. <i>The American Review of Respiratory Disease</i> , 1989, 140, 1450-1454.	2.9	7
122	Variable Tracheal Stenosis Related to Body Position. <i>Chest</i> , 1984, 86, 87-89.	0.4	2